Kathy S. Frommer Elected to the Board of Directors
CHESTER, N.Y.–(BUSINESS WIRE)–Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS
Medical”) today announced that shareholders voted in favor of all
items of business put forth at the company’s Annual Meeting of
Shareholders held on April 23, 2019 in Chester, NY.
Shareholders elected director nominee Kathy S. Frommer as a new,
independent member of the Board of Directors succeeding Mark L.
Pastreich. Shareholders also re-elected Daniel S. Goldberger, Robert T.
Allen, David W. Anderson, James M. Beck, Joseph M. Manko, Jr., and
Arthur J. Radin to the Board of Directors. As previously announced, Mr.
Radin died unexpectedly on April 24, 2019.
“On behalf of the Board of Directors, I want to welcome Kathy Frommer to
her new role and thank Mark Pastreich for his many years of loyal
service to RMS Medical,” said Daniel S. Goldberger, Executive Chairman.
“We believe we are well-positioned to expand our business and elevate
our profile in the growing home and alternate site infusion industry.”
Ms. Frommer brings more than 30 years of experience in the information
technology industry to RMS Medical. In 1989, she co-founded CRS Retail
Systems (“CRS”), one of the largest providers of software for specialty
store retailers in the United States and served as Chief Executive
Officer until its acquisition by Epicor Software in 2005. During her
tenure at CRS, Ms. Frommer successfully guided the company through
extensive growth, multiple acquisitions, and major technology
initiatives, as well as a successful partnership with private equity
firm Accel-KKR. With systems installed worldwide, the solutions offered
by CRS helped its customers drive sales, improve customer service and
reduce operating costs. Prior to CRS, Ms. Frommer worked as a systems
engineer with various technology companies. She currently serves on the
Board of the SUNY Orange College Foundation and the Bethel Woods Center
for the Arts.
Shareholders also approved, on an advisory basis, the compensation of
RMS Medical’s executive officers and the frequency of future votes on
executive compensation; the ratification of the appointment of RMS
Medical’s independent registered public accountants for the 2019 fiscal
year; and an increase in the maximum number of shares that may be
awarded under the 2015 Stock Option Plan.
About RMS Medical Products
RMS Medical develops, manufactures and commercializes innovative and
easy-to-use specialty infusion solutions that improve quality of life
for patients around the world. The FREEDOM Syringe Infusion System
currently includes the FREEDOM60® and FreedomEdge®
Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and
RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices
are used for infusions administered in the home and alternate care
settings. For more information about RMS Medical, please visit www.rmsmedicalproducts.com.
The statements contained herein may include prospects, statements of
future expectations and other forward-looking statements that are based
on management’s current views and assumptions and involve known and
unknown risks and uncertainties, identified by words such as “believe”.
Actual results, performance or events may differ materially from those
expressed or implied in such forward-looking statements. RMS Medical
undertakes no obligation to update any forward-looking statements.
The Equity Group Inc.
Kalle Ahl, CFA